Platelet-rich plasma is a growing part of "regenerative" medicine. It's natural, easily applied and a profit center for companies and physicians. But what remains unclear is whether its use is beneficial to patients.
The FDA's current regulatory framework is out of whack -- and it comes at the expense of patient safety. The Wild West of "stem cell" clinics continues. This time, patients are hospitalized with blood infections to spinal abscesses.
Though we're often told that with every new digital health product, medication or device, biotech firm or health-system launch how "groundbreaking," "revolutionary" or "disruptive" it is, here's an ongoing medical reality that actually is just those things.
Does Geisinger Health System's latest pitch, to offer DNA sequencing as part of routine testing at the primary care visit, promise more than it can deliver?
Newly released guidelines from the U.S. Food and Drug Administration (FDA) suggest illegitimate, unproven stem cell uses might become a thing of the past.
The urine of premature infants is chock full of progenitor cells, which could have major clinical significance in restoring function to damaged kidneys.
Leon Bellan, an assistant professor of mechanical engineering at Vanderbilt University, used his creative vision and a $40 cotton candy machine to create tiny threads that resemble patterns formed by capillaries. In the body, these may be able to keep tissues viable and functional for transplantation.